England’s cancer services face a substantial gap to a 2027 treatment goal after the proportion of patients starting treatment within 62 days fell in the latest monthly figures.
In September 2026, 70.7 per cent of people whose treatment was recorded under the two-month measure began their first treatment within that period. The figure was 71.9 per cent in August. The September result was 9.3 percentage points below the 80 per cent milestone set for March 2027.
Without improvement, the current level of performance leaves the goal at risk. The result for a single month does not, however, establish what will happen by the deadline. Performance can change as services handle different numbers of patients and work through their waiting lists.
What the treatment measure covers
The 62-day measure tracks the time to first definitive treatment for people with cancer after an urgent suspected cancer referral, an urgent referral for breast symptoms, an urgent screening referral or an upgrade by a consultant. The percentage describes people who started treatment in the month and whose care was included in that measure; it is not the proportion of everyone referred with possible cancer.
In September, 30,522 referrals were recorded under the combined 62-day standard, up from 27,909 in August. The increase in the volume covered by the measure is separate from the decrease in the percentage treated within the standard. A change in either number alone does not explain why performance moved between the months.
The figures, released on 12 November, are provisional. Some records from one trust were missing information needed for inclusion in the 62-day measure. The estimated shortfall in national activity for that measure was 0.41 per cent, with a very small estimated effect on performance. The data can be revised.
A milestone and a longer-term standard
The 80 per cent figure is an interim planning milestone, not the full 62-day operational standard. The longer-standing standard is that 85 per cent of patients should begin first treatment within 62 days. The current planning framework calls for every trust to reach 80 per cent by March 2027, with the 85 per cent standard to be maintained by the end of 2028–29.
The national cancer plan also sets out the ambition to meet the cancer waiting-time standards by March 2029. The distinction matters: falling short of the 2027 milestone would be different from missing the full 85 per cent standard, which is already above the level recorded in September.
The latest monthly result also needs to be read alongside the longer trend. Performance on the 62-day measure averaged 70.4 per cent over the 12 months to September 2026, compared with 69.0 per cent in the preceding 12 months. That shows an improvement in the annual average despite the fall between August and September. It does not guarantee the pace of improvement needed to reach the interim milestone.
Diagnosis and treatment are measured separately
The two-month treatment measure is one of three cancer waiting-time standards. Another looks at how quickly people receive a diagnosis or have cancer definitively ruled out after an urgent referral. In September, 76.2 per cent received that outcome within 28 days, compared with 78.6 per cent in August. The standard is 80 per cent.
The third measure covers the time from a decision to treat, or the earliest clinically appropriate date, to the start of first or subsequent treatment. In September, 91.5 per cent started within 31 days, down from 92.1 per cent in August. The standard is 96 per cent.
These percentages cannot be treated as interchangeable. The faster-diagnosis measure includes people who are told they do not have cancer, while the 62-day measure concerns the start of first cancer treatment. The 31-day measure can also include subsequent treatment. Each therefore captures a different part of the pathway.
For patients and families, waiting for tests, results or treatment can be distressing. The time needed for an individual pathway can vary with the tests required and the type of treatment being planned. A national percentage does not show what happened to any particular person, why an individual wait occurred or what its clinical effect will be.
Meeting the interim milestone would require a higher proportion of patients to start treatment within the 62-day period than did so in September. Whether that happens will depend on results in the months ahead, rather than on the latest snapshot alone.